# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

NATtrol Vaginal Panel External Run Controls

D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>PMN</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.3920 -Assayed Quality ControlMaterial For ClinicalMicrobiology Assays</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr></table>

# II Submission/Device Overview:

# A Purpose for Submission:

To obtain a substantial equivalence determination for the NATtrol BD MAX Vaginal Panel External Controls

# B Measurand:

DNA sequences from the following eight (8) microorganisms:

• Lactobacillus jensenii Gardnerella vaginalis Atopobium vaginae Saccharomyces cerevisiae containing BVAB2 (Bacterial Vaginosis-Associated Bacterium 2) sequence   
• Candida albicans

• Candida krusei • Candida glabrata Trichomonas vaginalis

# C Type of Test:

The NATtrol BD MAX Vaginal Panel External Controls are intended for in vitro diagnostic use as external assayed quality control materials to monitor the qualitative amplification, detection and identification steps of the laboratory nucleic acid test, the BD MAX Vaginal Panel.

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

NATtrol BV Negative Control (NATBVNEG-BD) is intended for use as an assayed quality control material to monitor the performance of in vitro diagnostic laboratory nucleic acid testing procedures for the qualitative detection of targets on the BD Vaginal Panel for BD MAX System. NATtrol BV Negative Control is a qualitative control containing intact and inactivated Lactobacillus crispatus and intended to be used solely with the BD Vaginal Panel for BD MAX System. This product is not intended to replace manufacturer controls provided in the package insert.

NATtrol BV Positive Control (NATBVPOS-BD) is intended for use as an assayed quality control material to monitor the performance of in vitro diagnostic laboratory nucleic acid testing procedures for the qualitative detection of targets on the BD Vaginal Panel for BD MAX System. NATtrol BV Positive Control is a qualitative control containing intact and inactivated Lactobacillus jensenii, Gardnerella vaginalis, Atopobium vaginae, and Saccharomyces cerevisiae containing BVAB2 (Bacterial Vaginosis-Associated Bacterium 2) sequence and intended to be used solely with the BD Vaginal Panel for BD MAX System. This product is not intended to replace manufacturer controls provided in the package insert.

NATtrol Candida/TV Positive Control (NATCTVPOS-BD) is intended for use as an assayed quality control material to monitor the performance of in vitro diagnostic laboratory nucleic acid testing procedures for the qualitative detection of targets on the BD Vaginal Panel for BD MAX System. NATtrol Candida/TV Positive Control is a qualitative control containing intact and inactivated Candida albicans, Candida krusei, Candida glabrata, and Trichomonas vaginalis and intended to be used solely with the BD Vaginal Panel for the BD MAX System. This product is not intended to replace manufacturer controls provided in the package insert.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only

# D Special Instrument Requirements:

NATtrol BD MAX Vaginal Panel External Controls are intended for use on the BD MAX System.

# IV Device/System Characteristics:

# A Device Description:

NATtrol BD MAX Vaginal Panel External Controls are formulated with purified, intact microorganisms that have been chemically modified to render them non-infectious and refrigerator stable. The controls are formulated in a proprietary matrix that contains Fetal Bovine Serum, Human Serum Albumin, and sodium azide.

NATtrol BV Positive Control contains intact and inactivated Lactobacillus jensenii, Gardnerella vaginalis, Atopobium vaginae, and Saccharomyces cerevisiae containing BVAB2 (Bacterial Vaginosis-Associated Bacterium 2) sequence.

NATtrol Candida/TV Positive Control contains intact and inactivated Candida albicans, Candida krusei, Candida glabrata, and Trichomonas vaginalis.

NATtrol BV Negative Control contains intact and inactivated Lactobacillus crispatus.

# B Principle of Operation:

Contains organism targets for the BD Vaginal Panel Assay to monitor the performance of the assay over time, as performed on the BD MAX System.

# V Substantial Equivalence Information:

A Predicate Device Name(s): BD MAX CT/GC/TV 20-Day QC Panel

B Predicate 510(k) Number(s): K181683

C Comparison with Predicate(s):

<table><tr><td rowspan=1 colspan=1>Device &amp; PredicateDevice(s):</td><td rowspan=1 colspan=1>K201403</td><td rowspan=1 colspan=1>K181683</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=1>NATrol BD MAXVaginal Panel ExternalRun Controls</td><td rowspan=1 colspan=1>BD MAX CT/GC/TV20-Day QC Panel</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Similarities</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use/IndicationsFor Use</td><td rowspan=1 colspan=1>NATtrol BV NegativeControl (NATBVNEG-BD) is intended for useas an assayed qualitycontrol material tomonitor theperformance of in vitro</td><td rowspan=1 colspan=1>The BD MAXCT/GC/TV 20-Day QCPanel is intended foruse as an externalassayed positive qualitycontrol material tomonitor the</td></tr></table>

<table><tr><td>procedures for the qualitative detection of targets on the BD Vaginal Panel for BD MAX System. NATtrol BV Negative Control is a qualitative control containing intact and inactivated Lactobacillus crispatus and intended to be used solely with the BD Vaginal Panel for BD MAX System. This product is not intended to replace manufacturer controls provided in the package insert. NATtrol BV Positive Control (NATBVPOS- BD is intended for use as an assayed quality control material to monitor the performance of in vitro diagnostic laboratory nucleic acid testing procedures for the qualitative detection of targets on the BD Vaginal Panel for BD MAX System. NATtrolTM BV Positive Control is a qualitative control containing intact and inactivated Lactobacillus jensenii, Gardnerella vaginalis, Atopobium vaginae, and Saccharomyces cerevisiae containing BVAB2 (Bacterial Vaginosis-Associated Bacterium 2) sequence and intended to be used</td><td>testing procedures for the qualitative detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis with the BD MAX CT/GC/TV Assay on the BD MAX System. The controls comprise cultured and inactivated C. trachomatis, N. gonorrhoeae and T. vaginalis. The BD MAX CT/GC/TV 20- Day QC Panel is not intended to replace manufacturer controls provided with the device.</td></tr></table>

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">solely with the BDVaginal Panel for BDMAX System. Thisproduct is not intendedto replace manufacturercontrols provided in thepackage insert.NATtrol Candida/TVPositive Control(NATCTVPOS-BD) isintended for use as anassayed quality controlmaterial to monitor theperformance of in vitrodiagnostic laboratorynucleic acid testingprocedures for thequalitative detection oftargets on the BDVaginal Panel for BDMAX System.NATtrol Candida/TVPositive Control is aqualitative controlcontaining intact andinactivated Candidaalbicans, Candidakrusei, Candidaglabrata, andTrichomonas vaginalisand intended to be usedsolely with the BDVaginal Panel for theBD MAX System. Thisproduct is not intendedto replace manufacturercontrols provided in thepackage insert.</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Composition</td><td colspan="1" rowspan="1">Inactivatedmicroorganisms</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Test System</td><td colspan="1" rowspan="1">BD MAX System</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Steps Monitored</td><td colspan="1" rowspan="1">Extraction,amplification, anddetection</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Inactivated</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Y</td><td colspan="1" rowspan="1">microorganisms</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Physical Format</td><td colspan="1" rowspan="1">Read-to-use liquid</td><td colspan="1" rowspan="1">Lyophilized</td></tr><tr><td colspan="1" rowspan="1">Number of TargetsMonitored</td><td colspan="1" rowspan="1">Eight (8): Lactobacillusjensenii, Gardnerellavaginalis, Atopobiumvaginae,Saccharomycescerevisiae, Candidaalbicans, Candidakrusei, Candidaglabrata, andTrichomonas vaginalis</td><td colspan="1" rowspan="1">Three (3): Chlamydiatrachomatis, Neisseriagonorrhoeae andTrichomonas vaginalis</td></tr></table>

# VI Standards/Guidance Documents Referenced:

Special Controls under 21 CFR 866.3920

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

# 1. Precision/Reproducibility:

An external site precision study was performed with the NATtrol BD MAX Vaginal Panel External Run Controls on the BD Max system. The performance of the controls was evaluated by observing the data collected during multiple studies performed by six (6) operators using two (2) lots of BV Positive (NATBVPOS-BD), two (2) lots of BV Negative (NATBVNEG-BD), and one (1) lot of CTV Positive (NATCTVPOS-BD) controls. All controls were added to the BD Molecular Swab Sample Buffer Tube and processed according to the BD Vaginal Panel Assay package insert. A total of 381 external controls were tested (86 BV Positive Controls, 104 CTV Positive Controls, and 191 BV Negatives). The results are shown in the Tables below:

Table 1: BV Positive Control Precision Study Summary   

<table><tr><td rowspan=1 colspan=3>BV PositiveControl</td></tr><tr><td rowspan=1 colspan=1>Target</td><td rowspan=1 colspan=1>BD MAX Result(Observed/Total)</td><td rowspan=1 colspan=1>% Agreement withexpected Results(95% CI)</td></tr><tr><td rowspan=1 colspan=1>BV</td><td rowspan=1 colspan=1>Positive (84/86)</td><td rowspan=1 colspan=1>97.7%(91.9%-99.4%)</td></tr><tr><td rowspan=1 colspan=1>C group</td><td rowspan=1 colspan=1>Negative (86/86)</td><td rowspan=1 colspan=1>100%(95.7%-100%)</td></tr></table>

Table 2: BV Negative Control Precision Study Summary   

<table><tr><td rowspan=1 colspan=1>C. krusei</td><td rowspan=1 colspan=1>Negative (86/86)</td><td rowspan=1 colspan=1>100%(95.7%-100%)</td></tr><tr><td rowspan=1 colspan=1>C.glabrata</td><td rowspan=1 colspan=1>Negative (86/86)</td><td rowspan=1 colspan=1>100%(95.7%-100%)</td></tr><tr><td rowspan=1 colspan=1>TV</td><td rowspan=1 colspan=1>Negative (86/86)</td><td rowspan=1 colspan=1>100%(95.7%-100%)</td></tr></table>

Table 3: Candida/TV Positive Control Precision Study Summary   

<table><tr><td rowspan=1 colspan=3>BV Negative Control</td></tr><tr><td rowspan=1 colspan=1>Target</td><td rowspan=1 colspan=1>BD MAX Result(Observed/Total)</td><td rowspan=1 colspan=1>% Agreement withexpected Results(95% CI)</td></tr><tr><td rowspan=1 colspan=1>BV</td><td rowspan=1 colspan=1>Negative (191/191)</td><td rowspan=1 colspan=1>100%(98.0%-100%)</td></tr><tr><td rowspan=1 colspan=1>Cgroup</td><td rowspan=1 colspan=1>Negative (189/191)</td><td rowspan=1 colspan=1>99.0%(96.3%-99.7%)</td></tr><tr><td rowspan=1 colspan=1>C. krusei</td><td rowspan=1 colspan=1>Negative (191/191)</td><td rowspan=1 colspan=1>100%(98.0%-100%)</td></tr><tr><td rowspan=1 colspan=1>C.glabrata</td><td rowspan=1 colspan=1>Negative (191/191)</td><td rowspan=1 colspan=1>100%(98.0%-100%)</td></tr><tr><td rowspan=1 colspan=1>TV</td><td rowspan=1 colspan=1>Negative (191/191)</td><td rowspan=1 colspan=1>100%(98.0%-100%)</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Candida/TV Positive Control</td></tr><tr><td rowspan=1 colspan=1>Target</td><td rowspan=1 colspan=1>BD MAX Result(Observed/Total)</td><td rowspan=1 colspan=1>% Agreement withexpected Results(95% CI)</td></tr><tr><td rowspan=1 colspan=1>BV</td><td rowspan=1 colspan=1>Negative (102/104)</td><td rowspan=1 colspan=1>98.1%(93.3%-99.5%)</td></tr><tr><td rowspan=1 colspan=1>C group</td><td rowspan=1 colspan=1>Positive (103/104)</td><td rowspan=1 colspan=1>99.0%(94.8%-99.8%)</td></tr><tr><td rowspan=1 colspan=1>C. krusei</td><td rowspan=1 colspan=1>Positive (103/104)</td><td rowspan=1 colspan=1>99.0%(94.8%-99.8%)</td></tr><tr><td rowspan=1 colspan=1>C.glabrata</td><td rowspan=1 colspan=1>Positive (103/104)</td><td rowspan=1 colspan=1>99.0%(94.8%-99.8%)</td></tr><tr><td rowspan=1 colspan=1>TV</td><td rowspan=1 colspan=1>Positive (103/104)</td><td rowspan=1 colspan=1>99.0%(94.8%-99.8%)</td></tr></table>

Table 4: BV Positive Control Precision Study Stratified by Operator and Lot   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Lot Number</td></tr><tr><td rowspan=1 colspan=1>Operator</td><td rowspan=1 colspan=1>320306</td><td rowspan=1 colspan=1>322104</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>5/5 (100%)</td><td rowspan=1 colspan=1>5/5 (100%)</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>12/12 (100%)</td><td rowspan=1 colspan=1>3/3 (100%)</td><td rowspan=1 colspan=1>15/15 (100%)</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>3/3 (100%)</td><td rowspan=1 colspan=1>3/3 (100%)</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3/3 (100%)</td><td rowspan=1 colspan=1>12/12 (100%)</td><td rowspan=1 colspan=1>15/15 (100%)</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3/3 (100%)</td><td rowspan=1 colspan=1>43/45 (95.55%)</td><td rowspan=1 colspan=1>46/48 (95.8%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>18/18 (100%)</td><td rowspan=1 colspan=1>66/68(97.05%)</td><td rowspan=1 colspan=1>84/86 (97.7%)</td></tr></table>

Table 5: Candida/TV Positive Control Precision Study Stratified by Operator   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Lot Number</td></tr><tr><td rowspan=1 colspan=1>Operator</td><td rowspan=1 colspan=1>322106</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5/5 (100%)</td><td rowspan=1 colspan=1>5/5 (100%)</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>9/9 (100%)</td><td rowspan=1 colspan=1>9/9 (100%)</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3/4 (75%)</td><td rowspan=1 colspan=1>3/4 (75%)</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>15/15 (100%)</td><td rowspan=1 colspan=1>15/15 (100%)</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>67/68 (98.5%)</td><td rowspan=1 colspan=1>67/68 (98.5%)</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>3/3 (100%)</td><td rowspan=1 colspan=1>3/3 (100%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>102/104 (98.1%)</td><td rowspan=1 colspan=1>102/104 (98.1%)</td></tr></table>

Table 6: BV Negative Control Precision Study Stratified by Operator and Lot   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Lot Number</td></tr><tr><td rowspan=1 colspan=1>Operator</td><td rowspan=1 colspan=1>322123</td><td rowspan=1 colspan=1>321575</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10/10 (100%)</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>10/10 (100%)</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>12/12 (100%)</td><td rowspan=1 colspan=1>12/12 (100%)</td><td rowspan=1 colspan=1>24/24 (100%)</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7/7 (100%)</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>7/7 (100%)</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>27/27 (100%)</td><td rowspan=1 colspan=1>3/3 (100%)</td><td rowspan=1 colspan=1>30/30 (100%)</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>112/114 (98.2%)</td><td rowspan=1 colspan=1>3/3(100%)</td><td rowspan=1 colspan=1>115/117(98.3%)</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>3/3 (100%)</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>3/3 (100%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>171/173 (98.8%)</td><td rowspan=1 colspan=1>18/18 (100%)</td><td rowspan=1 colspan=1>189/191 (99.0%)</td></tr></table>

The precision study results establish there is no significant difference in control performance among different operators and between lots.

Table 7: NATrol BD MAX Vaginal Panel External Run Controls Precision Study Stratified By Lot   

<table><tr><td colspan="1" rowspan="1">Target (Lot)</td><td colspan="1" rowspan="1">External Run Control</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">MeanCt</td><td colspan="1" rowspan="1">Ct SD</td><td colspan="1" rowspan="1">Ct%CV</td></tr><tr><td colspan="1" rowspan="1">BV-GV (320306)</td><td colspan="1" rowspan="3">NATBVPOS-BD</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">21.1</td><td colspan="1" rowspan="1">0.30</td><td colspan="1" rowspan="1">1.4%</td></tr><tr><td colspan="1" rowspan="1">BV-GV (322104)</td><td colspan="1" rowspan="1">66</td><td colspan="1" rowspan="1">21.0</td><td colspan="1" rowspan="1">0.42</td><td colspan="1" rowspan="1">2.0%</td></tr><tr><td colspan="1" rowspan="1">BV-GV (AII)</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">21.0</td><td colspan="1" rowspan="1">0.40</td><td colspan="1" rowspan="1">1.9%</td></tr><tr><td colspan="1" rowspan="1">BV-Atopobium vaginae (320306)</td><td colspan="1" rowspan="3">NATBVPOS-BD</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">19.7</td><td colspan="1" rowspan="1">0.35</td><td colspan="1" rowspan="1">1.8%</td></tr><tr><td colspan="1" rowspan="1">BV-Atopobium vaginae (322104)</td><td colspan="1" rowspan="1">66</td><td colspan="1" rowspan="1">21.4</td><td colspan="1" rowspan="1">0.47</td><td colspan="1" rowspan="1">2.2%</td></tr><tr><td colspan="1" rowspan="1">BV-Atopobium vaginae (All)</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">21.0</td><td colspan="1" rowspan="1">0.82</td><td colspan="1" rowspan="1">3.9%</td></tr><tr><td colspan="1" rowspan="1">Lactobacillus spp. (320306)</td><td colspan="1" rowspan="3">NATBVPOS-BD</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">30.7</td><td colspan="1" rowspan="1">1.38</td><td colspan="1" rowspan="1">4.5%</td></tr><tr><td colspan="1" rowspan="1">Lactobacillus spp. (322104)</td><td colspan="1" rowspan="1">66</td><td colspan="1" rowspan="1">25.7</td><td colspan="1" rowspan="1">0.76</td><td colspan="1" rowspan="1">2.9%</td></tr><tr><td colspan="1" rowspan="1">Lactobacillus spp. (All)</td><td colspan="1" rowspan="1">83</td><td colspan="1" rowspan="1">26.7</td><td colspan="1" rowspan="1">2.21</td><td colspan="1" rowspan="1">8.3%</td></tr><tr><td colspan="1" rowspan="1">BVAB-2 (320306)</td><td colspan="1" rowspan="3">NATBVPOS-BD</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">22.5</td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">0.9%</td></tr><tr><td colspan="1" rowspan="1">BVAB-2 (322104)</td><td colspan="1" rowspan="1">66</td><td colspan="1" rowspan="1">22.2</td><td colspan="1" rowspan="1">0.24</td><td colspan="1" rowspan="1">1.1%</td></tr><tr><td colspan="1" rowspan="1">BVAB-2 (AIl)</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">22.3</td><td colspan="1" rowspan="1">0.25</td><td colspan="1" rowspan="1">1.1%</td></tr><tr><td colspan="1" rowspan="1">TV (322106)</td><td colspan="1" rowspan="4">NATCVPOS-BD</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">26.1</td><td colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1">1.0%</td></tr><tr><td colspan="1" rowspan="1">C group (322106)</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">25.2</td><td colspan="1" rowspan="1">0.40</td><td colspan="1" rowspan="1">1.6%</td></tr><tr><td colspan="1" rowspan="1">C. krusei (322106)</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">25.2</td><td colspan="1" rowspan="1">0.34</td><td colspan="1" rowspan="1">1.3%</td></tr><tr><td colspan="1" rowspan="1">C. glabrata (322106)</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">30.1</td><td colspan="1" rowspan="1">2.11</td><td colspan="1" rowspan="1">7.0%</td></tr><tr><td colspan="1" rowspan="1">Lactobacillus spp.(321575)</td><td colspan="1" rowspan="3">NATBVNEG-BD</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">23.7</td><td colspan="1" rowspan="1">0.22</td><td colspan="1" rowspan="1">0.9%</td></tr><tr><td colspan="1" rowspan="1">Lactobacillus spp. (322123)</td><td colspan="1" rowspan="1">171</td><td colspan="1" rowspan="1">22.5</td><td colspan="1" rowspan="1">0.44</td><td colspan="1" rowspan="1">1.9%</td></tr><tr><td colspan="1" rowspan="1">Lactobacillus spp. (All)</td><td colspan="1" rowspan="1">189</td><td colspan="1" rowspan="1">22.6</td><td colspan="1" rowspan="1">0.56</td><td colspan="1" rowspan="1">2.5%</td></tr></table>

The results confirm there is no significant difference in Ct values for controls between different lots of BV Positive Controls and BV Negative Controls.

Overall, the precision study results are acceptable.

2. Linearity: Not applicable.

3. Analytical Specificity/Interference: Not applicable.

4. Assay Reportable Range: Not applicable.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

# Real-Time Stability Program:

The NATtrol BD MAX Vaginal Panel External Controls stability study is an ongoing study designed to support a 12-month shelf-life claim at $2 { - } 8 ^ { \circ } \mathrm { C }$ . Testing is performed at multiple timepoints within the anticipated shelf-life with an additional test performed at least four (4) months after the proposed expiration date. The BD MAX Vaginal Panel will be used to test each control three times at each time point according to the package insert instructions for use. Acceptance criteria for each test is a positive or negative result for the appropriate targets at all time points.

The controls were tested using the BD MAX Vaginal Panel with the UVE Sample Buffer Tube for initial stability testing. Release testing (post dispense and assembly) of each lot served as the initial time point of the study (T0). For Real-Time Stability, controls in their final packaging were placed at $2 { - } 8 ^ { \circ } \mathrm { C }$ , and three replicates $( \mathtt { n } = 3 )$ ) from three separate tubes were tested at each time point per the testing methods. All three replicates for each control produced the same expected result, which is summarized in Table 8.

Table 8: Summary of Initial Real Time Stability Testing   

<table><tr><td rowspan=1 colspan=1>NATrol BD MAX VaginalPanel External Controls</td><td rowspan=1 colspan=1>Lot</td><td rowspan=1 colspan=1>Final time point(months)</td><td rowspan=1 colspan=1>Summary of Results atEach Time Point</td></tr><tr><td rowspan=6 colspan=1>NATBVPOS-BD</td><td rowspan=1 colspan=1>316984</td><td rowspan=1 colspan=1>12</td><td rowspan=6 colspan=1>BV POS</td></tr><tr><td rowspan=1 colspan=1>318513</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>319891</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>320306</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>321997</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>322104</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=3 colspan=1>NATBVNEG-BD</td><td rowspan=1 colspan=1>320307</td><td rowspan=1 colspan=1>25</td><td rowspan=3 colspan=1>Cgroup POS, CkruPOS, Cgla POS,TV POS</td></tr><tr><td rowspan=1 colspan=1>321575</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>322123</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=4 colspan=1>NATCTVPOS-BD</td><td rowspan=1 colspan=1>318697</td><td rowspan=1 colspan=1>13</td><td rowspan=4 colspan=1>BV NEG</td></tr><tr><td rowspan=1 colspan=1>319920</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>320966</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>322106</td><td rowspan=1 colspan=1>18</td></tr></table>

Real-time stability study protocols, acceptance criteria, and initial results were reviewed and found to be acceptable.

6. Detection Limit: Not applicable.

7. Assay Cut-Off: Not applicable.

# B Comparison Studies:

1. Method Comparison with Predicate Device: Not applicable.

2. Matrix Comparison: Not applicable.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable.

# D Clinical Cut-Off:

Not applicable.

# E Expected Values/Reference Range:

NATrol BD MAX Vaginal Panel External Run Controls are qualitative controls, and the expected results are listed in Table 9.

Table 9: Expected Results for Each NATrol BD MAX Vaginal Panel External Control   

<table><tr><td rowspan=1 colspan=1>Target</td><td rowspan=1 colspan=1>BV Positive Control</td><td rowspan=1 colspan=1>BV Negative Control</td><td rowspan=1 colspan=1>CTV Positive Control</td></tr><tr><td rowspan=1 colspan=1>BV</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>C. group</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>C. krusei</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>C. glabrata</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>TV</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr></table>

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.